MHC class I presented antigens from malignancies: A perspective on analytical characterization & immunogenicity.
J Proteomics. 2018 Apr 23;:
Authors: Schmidt M, Lill JR
The field of cancer immunotherapy has expanded rapidly in the past few years, with many new approaches entering the clinic for T cell mediated killing of tumors. Several of these clinical approaches involve the exploitation of a CD8 + T cell response against MHC I presented tumor antigens. Here, we describe the types of tumor antigens which are considered as targets in the design of T cell based therapeutic approaches, the rationale for targeting MHC I antigens and the analytical tools commonly employed for the discovery of MHC I presented peptides. The advantages and disadvantages of each approach are discussed and a perspective on the future directions of the MHC I peptide exploration field and biotherapeutic strategies is given.
SIGNIFICANCE: This work is the first review time an article has been written to show summarize all the various types of tumor antigens, and the analytical tools employed to discover and characterize them.
PMID: 29698800 [PubMed – as supplied by publisher]